Daniel A Pollyea
Overview
Explore the profile of Daniel A Pollyea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
9875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santos J, Abbott D, Bosma G, Kent A, Schwartz M, McMahon C, et al.
Leuk Lymphoma
. 2025 Mar;
:1-3.
PMID: 40080662
No abstract available.
2.
Lachowiez C, Ravikumar V, Othman J, ONions J, Peters D, McMahon C, et al.
Blood
. 2024 Nov;
144(26):2788-2792.
PMID: 39486083
The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene...
3.
Gil K, Abbott D, Amaya M, Schwartz M, Gutman J, Kent A, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2228-2230.
PMID: 39229898
No abstract available.
4.
Kent A, Gil K, Jones M, Linden B, Purev E, Haverkos B, et al.
Transplant Cell Ther
. 2024 Aug;
PMID: 39154914
Despite the concurrent use of haploidentical cord (HCT) and dual cord (DCT) stem cell transplant approaches for over a decade, there have been few comparisons of their outcomes. Our objective...
5.
Dohner H, Pratz K, DiNardo C, Wei A, Jonas B, Pullarkat V, et al.
Blood
. 2024 Aug;
144(21):2211-2222.
PMID: 39133921
The European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems are based on response to intensive chemotherapy; their ability to discriminate outcomes in older patients treated with venetoclax-azacitidine...
6.
Marvin-Peek J, Gilbert J, Pollyea D, DiNardo C
Am J Hematol
. 2024 Jul;
99(9):1790-1801.
PMID: 39016070
The advent of molecularly targeted therapeutics has transformed the management of patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive chemotherapy, lower intensity therapies (LIT) incorporating small...
7.
Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, et al.
Haematologica
. 2024 Jun;
110(1):103-116.
PMID: 38934082
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due, at least in part, to drug resistance of leukemia stem cells (LSC). Recent clinical evidence suggests that...
8.
Fang J, Bosma G, Aisner D, McMahon C, Amaya M, Schwartz M, et al.
Leuk Lymphoma
. 2024 May;
65(6):800-807.
PMID: 38814858
Predictors for response to intensive therapy in AML have focused on baseline factors: percent leukemic blasts in marrow, cytogenetic/molecular genetic abnormalities, and presence of secondary AML. Non-baseline dynamic factors, occurring...
9.
Sheth A, Althoff M, Tolison H, Engel K, Amaya M, Krug A, et al.
Cancer Discov
. 2024 May;
14(10):1922-1939.
PMID: 38787341
Acute myeloid leukemia stem cells (LSCs) are uniquely reliant on oxidative phosphorylation (OXPHOS) for survival. Moreover, maintenance of OXPHOS is dependent on BCL-2, creating a therapeutic opportunity to target LSCs...
10.
Konopleva M, Dail M, Daver N, Garcia J, Jonas B, Yee K, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Feb;
24(6):364-374.
PMID: 38378362
Background: Therapies for relapsed/refractory acute myeloid leukemia remain limited and outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or targeted therapies. Patients And Methods: This phase 1b...